首页> 外文OA文献 >Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study
【2h】

Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study

机译:在专家指导下的低热量饮食下,在GP环境中使用西布曲明长期维持体重减轻:双盲,安慰剂对照,平行分组研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objective: Very-low-calorie diets (VLCDs) are used to promote short-term weight loss in obese patients. However, long-term maintenance of weight loss is generally poor. We assessed the efficacy and safety of sibutramine in maintaining weight loss achieved in obese patients by means of a 3-month VLCD. Design: A multicenter double-blind, parallel-group trial conducted over 18 months, following a 3-month open label VLCD run-in. Setting: Eight hospital centers in The Netherlands, with subsequent follow-up in general practice. Subjects: A total of 221 obese subjects, of whom 189 were randomized (mean screening BMI 36.6 kg/m(2); mean age 42.6y). Measurements: Patients were given a 3-month VLCD and were required to lose 10% or more of their initial weight. A total of 189 patients completed this phase (mean percentage weight loss 14.5 +/- 3.2%) and were randomized to sibutramine 10 mg/day (n = 94) or matching placebo (n = 95). All patients received a recommended diet and exercise program. The primary analysis was outcome in terms of achieving 80% weight maintenance of the VLCD period at month 18. Secondary analysis was percentage of initial weight loss maintained at months 6, 12, 18 and end point
机译:目的:低热量饮食(VLCD)用于促进肥胖患者的短期体重减轻。但是,减肥的长期维持通常较差。我们通过3个月的VLCD评估了西布曲明维持肥胖患者体重减轻的功效和安全性。设计:经过3个月的开放标签VLCD磨合,在18个月内进行了一项多中心双盲,平行组试验。地点:荷兰的八个医院中心,随后进行常规随访。受试者:总共221名肥胖受试者,其中189名是随机分组的(平均BMI筛查36.6 kg / m(2);平均年龄42.6y)。测量:为患者提供了3个月的VLCD,并要求他们减轻其初始体重的10%或更多。总共189名患者完成了该阶段(平均体重减轻14.5 +/- 3.2%),并随机分配至西布曲明10毫克/天(n = 94)或匹配的安慰剂(n = 95)。所有患者均接受推荐的饮食和运动计划。主要分析是在18个月时VLCD达到80%体重减轻的结果。次要分析是在6、12、18个月和终点保持初始体重减轻的百分比

著录项

  • 作者

    Mathus-Vliegen, E. M. H.;

  • 作者单位
  • 年度 2005
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号